Fortress Biotech stock fell 1.93 percent on October 2
Published on 10/04/2026 at 22:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fortress Biotech (ISIN US34960Q3074) stock closed at USD 2.03 on Nasdaq on October 2, 2026, down 1.93 percent from the prior session. The immediate company catalyst was a USD 15.0 million repayment that eliminated the remaining principal under Fortress Biotech's Oaktree credit facility, according to TradingView on October 1, 2026.
Debt falls by USD 15.0 million
The repayment covered the remaining principal of the senior secured facility and followed a USD 50.0 million original commitment. Fortress Biotech also paid USD 435,000 in accrued interest and a USD 150,000 prepayment fee, after which liens securing the agreement were released, TradingView reported.
That balance-sheet step matters because Fortress Biotech's equity value was USD 67.4 million on October 2, 2026. The repaid principal therefore equaled 22.2 percent of that market capitalization, a comparison that puts the financing event in scale for this small-cap biotechnology company.
Revenue reaches USD 18.7 million
Fortress Biotech reported total net revenue of USD 18.7 million for Q2 2026, up 14 percent from Q2 2025, according to GlobeNewswire in its September 8, 2026 company update. The reporting period ended June 30, 2026.
The company describes its model as a mix of marketed prescription products, development-stage candidates, equity holdings and royalty income. Its portfolio spans oncology, dermatology and rare diseases, while the investor-relations site lists ZYCUBO as a marketed product and multiple partner programs in clinical development.
Consensus target stays above the stock
A September 14, 2026 consensus page from Rallies showed one analyst covering FBIO, with a Buy consensus and a USD 5.00 average price target. The price target lies 146.31 percent above the October 2 price of USD 2.03.
For investors, the contrast is clear: revenue growth and debt reduction improve the operating narrative, while the stock still trades 55.19 percent below its 52-week high of USD 4.53. The next reported earnings date listed for FBIO is November 12, 2026.
FBIO closes at USD 2.03
FBIO closed at USD 2.03 on Nasdaq on October 2, 2026, with volume of 327,172 shares and a 52-week range of USD 2.01 to USD 4.53.
Fortress Biotech stock facts
- Company: Fortress Biotech, Inc.
- ISIN: US34960Q3074
- Ticker: FBIO
- Trading venue: Nasdaq Capital Market
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 2.03, closing price
- Market capitalization: USD 67.4 million (as of October 2, 2026)
- 52-week range: USD 2.01-4.53 (as of October 2, 2026)
- Sector / Industry: Healthcare / Biotechnology
Upcoming dates for Fortress Biotech stock
- November 12, 2026: Q3 2026 earnings report
